Market Overview

UPDATE: Cantor Fitzgerald Reiterates Buy Rating, Raises PT on CVS Caremark Corporation

Share:
Related CVS
CVS Health Says Overdose-Reversal Drug Is Now Available Without A Prescription In Texas
Barron's Picks And Pans: Pharmacy-Benefit Managers, Mortgage Insurers And More
The Vetr community has downgraded $CVS to 3-Stars (Vetr)

In a report published Friday, Cantor Fitzgerald reiterated its Buy rating on CVS Caremark Corporation (NYSE: CVS), and raised its price target from $55.00 to $57.00.

Cantor Fitzgerald noted, “Despite some concerns over what CVS could possibly do for an encore following some exceptional tailwinds in 2012, the combination of a major dividend increase and very strong (above consensus) EPS guidance set the tone for a very upbeat analyst meeting. We liked what we heard in the management presentations and have greater conviction in our 2013 earnings outlook. We reiterate our BUY rating with a revised price target is $57 (from $55).”

CVS Caremark Corporation closed on Thursday at $48.50.

Latest Ratings for CVS

DateFirmActionFromTo
Jun 2016Morgan StanleyDowngradesEqual-weight
May 2016JefferiesMaintainsBuy
May 2016CitigroupMaintainsNeutral

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: Cantor FitzgeraldAnalyst Color Price Target Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!